Clovis Sets Brisk Development Timetable For Lung Cancer Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The oncology drug developer expects to file its third generation EGFR inhibitor for the treatment of NSCLC by the end of 2015, CEO Patrick Mahaffy told investors during an R&D day Jan. 27. Investors are enthusiastic about the potential of the drug, which could address a sizeable commercial market.
You may also be interested in...
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Biomarker-guided targeted therapy has become a standard approach to oncology R&D, but few new targeted drugs have reached the market for lung cancer. A new wave of research could change that, and improve the outlook for lung cancer treatment.
Radius Business Review Ends In Sale To Investment Funds
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.
What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.